Ginkgo Bioworks (DNA)
(Real Time Quote from BATS)
$0.27 USD
0.00 (-0.07%)
Updated Aug 12, 2024 02:46 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Income Statements
Fiscal Year end for Ginkgo Bioworks Holdings, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 251 | 478 | 314 | 0 | 54 |
Cost Of Goods | 54 | 204 | 130 | 0 | 0 |
Gross Profit | 197 | 273 | 184 | 0 | 54 |
Selling & Adminstrative & Depr. & Amort Expenses | 1,062 | 2,482 | 2,013 | 0 | 126 |
Income After Depreciation & Amortization | -864 | -2,209 | -1,828 | 0 | -72 |
Non-Operating Income | -28 | 88 | -7 | 0 | -46 |
Interest Expense | 0 | 0 | 2 | 0 | 2 |
Pretax Income | -893 | -2,121 | -1,838 | 0 | -120 |
Income Taxes | 0 | -15 | -1 | 0 | 0 |
Minority Interest | 0 | -1 | -7 | 0 | -1 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -893 | -2,106 | -1,837 | 0 | -120 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -893 | -2,105 | -1,830 | 0 | -119 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -793 | -2,165 | -1,799 | 0 | -61 |
Depreciation & Amortization (Cash Flow) | 72 | 44 | 29 | 0 | 11 |
Income After Depreciation & Amortization | -864 | -2,209 | -1,828 | 0 | -72 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 1,944.42 | 1,679.84 | 1,360.37 | NA | NA |
Diluted EPS Before Non-Recurring Items | -0.39 | -0.86 | -0.15 | NA | NA |
Diluted Net EPS (GAAP) | -0.46 | -1.25 | -1.39 | NA | NA |
Fiscal Year end for Ginkgo Bioworks Holdings, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 56.21 | 37.94 | 34.75 | 55.43 | 80.57 |
Cost Of Goods | 13.72 | 9.20 | 6.61 | 6.92 | 18.10 |
Gross Profit | 42.49 | 28.74 | 28.14 | 48.51 | 62.47 |
SG&A, R&D, and Dept/Amort Expenses | 265.43 | 206.75 | 206.26 | 334.90 | 246.62 |
Income After SG&A, R&D, and Dept/Amort Expenses | -222.94 | -178.01 | -178.12 | -286.39 | -184.15 |
Non-Operating Income | 5.95 | 12.12 | -33.68 | -16.52 | 10.90 |
Interest Expense | NA | 0.00 | 0.09 | 0.00 | 0.00 |
Pretax Income | -216.99 | -165.88 | -211.89 | -302.91 | -173.25 |
Income Taxes | 0.19 | 0.03 | -0.20 | -0.02 | 0.07 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -217.18 | -165.91 | -211.69 | -302.89 | -173.32 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -217.18 | -165.91 | -211.69 | -302.89 | -173.32 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 2,055.02 | 2,004.46 | 1,978.84 | 1,950.81 | 1,933.44 |
Diluted EPS Before Non-Recurring Items | -0.08 | -0.08 | -0.09 | -0.09 | -0.09 |
Diluted Net EPS (GAAP) | -0.11 | -0.08 | -0.10 | -0.16 | -0.09 |